Last edition
News about "Pfizer"
Pfizer Launches Cost Savings Programme on TrumpRx
Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.
Pfizer | 07/02/2026 | By News Bureau
UK Industry Body Finds Sanofi in Breach Over RSV Therapy Claims Against Pfizer
A UK pharmaceutical industry watchdog has ruled that Sanofi breached the country’s code of practice by making misleading claims about its respiratory syncytial virus (RSV) therapy in comparison with a rival product from Pfizer.
Pfizer | 04/02/2026 | By Darshana
Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss
Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.
Pfizer | 04/02/2026 | By News Bureau
Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer
New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.
Pfizer | 12/01/2026 | By News Bureau
Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India
Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.
Pfizer | 19/12/2025 | By News Bureau
Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer
Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.
Pfizer | 16/12/2025 | By News Bureau | 114
Yao Pharma and Pfizer Sign Exclusive Collaboration Deal
Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.
Pfizer | 10/12/2025 | By Akanki
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Pfizer | 24/11/2025 | By Dineshwori
Pfizer Completes Acquisition of Metsera
Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.
Pfizer | 14/11/2025 | By Dineshwori | 111
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
Pfizer | 14/11/2025 | By Darshana | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy